Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2-65
SponsorYasmin medhat munir Mohamed
About this trial
The purpose of this study is to develop a new tool that helps doctors choose the right cyclosporine dose for patients undergoing bone marrow transplantation. The tool is designed to predict the best dose using sparse sampling, making it practical for everyday clinical care. It combines information about population pharmacokinetics of cyclosporine with advanced artificial intelligence techniques, including machine learning and deep learning. This tool aims to improve treatment, personalize dosing for each patient, and reduce the risk of graft-versus-host disease.
Eligibility criteria
Qualifiers
• CsA therapy indicated alone or in combination for GVHD prophylaxis.
Aged 2-65 years.
Clinically stable after first HSCT.
Disqualifiers
• Inaccurate sampling or dose administration times.
Patients with missing key covariates.
Patients lacking sufficient pharmacokinetic or TDM data
Trial design
Treatments tested in this trial
- Not listed
Trial groups
300 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Yasmin medhat munir Mohamed
Lead sponsor
Helwan University
Sponsor institution
Source ClinicalTrials.gov